Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval
Published: April 06, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.
Read More
Lilly vs JPMorgan: Which Hits a $1 Trillion Market Cap First?
Published: April 06, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Eli Lilly (NYSE: LLY | LLY Price Prediction) and JPMorgan Chase (NYSE: JPM) both have market caps around $800 billion, putting them in a live race to a $1 trillion market cap.
Read More
Eli Lilly's Path to $1 Trillion Runs Directly Through the AI Boom
Published: April 06, 2026 by: 24/7 Wall Street
Sentiment: Positive
Eli Lilly (NYSE:LLY | LLY Price Prediction) has built one of the most remarkable growth stories in modern pharmaceutical history through its GLP-1 franchises.
Read More
MSFT, AVGO, LLY & Other Stock Market Opportunities Amid U.S.-Iran War
Published: April 02, 2026 by: Schwab Network
Sentiment: Neutral
There's always opportunity in markets if you know where to look, says Tiffany McGhee. She offers insight into how her firm positions portfolios in times of profound volatility, including now as the U.S.-Iran War drags on.
Read More
Global pharma companies that have publicly announced Trump drug pricing agreements
Published: April 02, 2026 by: Reuters
Sentiment: Positive
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-year exemptions from tariffs on drug imports.
Read More
Bank of America sees Eli Lilly's Foundayo as preferred oral GLP-1
Published: April 02, 2026 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) is entering the US market slightly ahead of schedule with its oral GLP-1 weight-loss therapy Foundayo, a move Bank of America says could expand the obesity market without cannibalizing the company's existing Zepbound product. In a note to clients, Bank of America reiterated its Buy rating on Lilly, citing the early approval and favorable labeling of Foundayo, also known as orforglipron.
Read More
Pricing and availability of Novo, Lilly's weight-loss drugs
Published: April 01, 2026 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Eli Lilly's oral weight-loss drug, orforglipron, branded as Foundayo, making it the second pill to enter the fast-growing obesity treatment market.
Read More
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Published: April 01, 2026 by: Reuters
Sentiment: Positive
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker's efforts to expand its foothold in the lucrative obesity market.
Read More
Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says
Published: April 01, 2026 by: CNBC
Sentiment: Negative
Eli Lilly opposes the White House's push to codify 'Most Favored Nations' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies that have signed MFN deals with the Trump administration.
Read More
Eli Lilly weight loss pill Foundayo approved by FDA, shares rise
Published: April 01, 2026 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity or those who are overweight with weight-related medical conditions, sending its shares more than 5% higher on Wednesday afternoon.
Read More
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Eli Lilly Stock Jumps. A Weight-Loss Pill Is Officially on the Market.
Published: April 01, 2026 by: Barrons
Sentiment: Positive
Eli Lilly's Foundayo will be available to patients through the drugmaker's online pharmacy.
Read More
Lilly's weight-loss pill wins US approval
Published: April 01, 2026 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's weight-loss pill, making it the second to market after Novo Nordisk's oral Wegovy, as the companies fight to capture more customers with the convenience of pills over injectables.
Read More
The FDA approved Eli Lilly's new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market
Published: April 01, 2026 by: WSJ
Sentiment: Positive
The FDA go-ahead tees up a battle with rival Novo Nordisk over the next front in the booming weight-loss drug market.
Read More
Cramer's Mad Dash: Eli Lilly
Published: April 01, 2026 by: CNBC Television
Sentiment: Neutral
CNBC's Jim Cramer delivers his daily Mad Dash.
Read More
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Published: April 01, 2026 by: PRNewsWire
Sentiment: Neutral
Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect ® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-pay INDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the …
Read More
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
Published: April 01, 2026 by: CNBC
Sentiment: Positive
The FDA approved a GLP-1 pill from Eli Lilly called Foundayo. Foundayo isn't as effective as Lilly's weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenience, and it can be scaled around the world, Lilly CEO Dave Ricks said.
Read More
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Neutral
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
Read More
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Published: March 31, 2026 by: Schaeffers Research
Sentiment: Positive
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion.
Read More
Lilly and Novo Show How AI Is Rewiring Big Pharma
Published: March 31, 2026 by: PYMNTS
Sentiment: Positive
Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients. Eli Lilly signed a $2.
Read More
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Published: March 31, 2026 by: Invezz
Sentiment: Positive
Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.
Read More
Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
Published: March 31, 2026 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash, with a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones. The acquisition adds Centessa's sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly's neuroscience business.
Read More
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Published: March 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space.
Read More
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY's obesity drugs fuel explosive growth, while ABBV depends on Skyrizi and Rinvoq. Let's see which drugmaker has the stronger 2026 outlook.
Read More
What's Going On With Eli Lilly On Monday?
Published: March 23, 2026 by: Benzinga
Sentiment: Neutral
More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions.
Read More
Why Eli Lilly Remains My Top Obesity Bet
Published: March 20, 2026 by: Seeking Alpha
Sentiment: Positive
Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $11.7 billion in Q4. Meanwhile, on March 19, Eli Lilly published promising clinical data on retatrutide for the treatment of type 2 diabetes.
Read More
Eli Lilly's next-generation obesity drug delivers strong results in late-stage trial
Published: March 19, 2026 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) has reported positive results from its late-stage trial of retatrutide, a next-generation obesity drug, demonstrating significant reductions in blood sugar levels and body weight. The Phase 3 TRANSCEND-T2D-1 trial evaluated retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon, in adults with type 2 diabetes whose blood sugar was not adequately controlled with diet and exercise.
Read More
TrumpRx lists many medicines at prices higher than paid in UK
Published: March 18, 2026 by: Reuters
Sentiment: Negative
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Read More
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Published: March 18, 2026 by: CNBC
Sentiment: Negative
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000